Paeds · allergy-and-immunology
Serum sickness and serum-sickness-like reactions
Also known as Serum sickness · Serum-sickness-like reaction · SSLR · Type III immune-complex drug reaction · Immune-complex hypersensitivity · Cefaclor reaction
A fellowship-grade approach to serum sickness and serum-sickness-like reactions in children: how to read the triad of rash, fever and arthralgia that erupts days to weeks after a drug or biologic, how to separate true immune-complex serum sickness (complement consumed) from the clinically identical but non-immune-complex serum-sickness-like reaction (complement normal), how to manage the acute episode with drug withdrawal, antihistamine and short-course corticosteroid, and how to make the avoidance and re-challenge decision that protects the child without condemning them to a lifetime label.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- Rash with fever and arthralgia or arthritis 6–21 days after a drug or biologic — think serum sickness or serum-sickness-like reaction
- Hypotension, stridor, respiratory compromise or mucosal blistering — this is NOT serum sickness; exclude anaphylaxis, SJS/TEN or DRESS first
- A serum-sickness picture after a monoclonal antibody or antithymocyte globulin with low complement — true immune-complex serum sickness; do not re-challenge
- Proteinuria, haematuria, rising creatinine or palpable purpura — renal or vasculitic involvement; admit and escalate
- Persistent fever, severe synovitis, serositis or organ dysfunction — severe serum sickness; treat with systemic corticosteroid and specialist input
- Labelling every child with a cefaclor reaction as permanently drug-allergic — most serum-sickness-like reactions do not demand lifelong avoidance
- Re-challenging after a true biologic-induced serum sickness — recurrence can be faster and more severe
Life stages
Care settings
Clinical exam formats
Board mappings
- General Paediatrics
- Recognise and manage serum sickness and serum-sickness-like reactions in children, including the distinction between true immune-complex serum sickness and the non-immune-complex serum-sickness-like reaction
- Apply the avoidance and re-challenge decision after a serum-sickness picture, individualising for SSLR rather than applying a blanket lifelong label
- Clinical Applications
- Medical Sciences
- Long Cases
- Short Cases
- Infection, Immunology and Rheumatology: recognises and manages drug hypersensitivity including serum sickness and serum-sickness-like reactions
- Patient management: applies stepwise symptomatic management and the avoidance decision
- Patient safety, including safe prescribing and recognition of adverse drug reactions
- Applied Knowledge in Practice (AKP)
- Foundation of Practice (FOP)
- Theory and Science (TAS)
- History
- Communication
- Video
- General Pediatrics Content Outline — Allergy and Immunology
- General Pediatrics Content Outline — Emergency and Critical Care
- General Pediatrics Content Outline — Universal Task 3: Diagnosis
- General Pediatrics Content Outline — Universal Task 4: Management and Treatment
- Patient Care 4: Clinical Reasoning
- Patient Care 5: Patient Management
- Systems-Based Practice 1: Patient Safety
- Medical Knowledge: Allergic and immunologic disorders
- Medical Expert
- Pediatrics: Foundations — Recognizing and managing drug hypersensitivity including serum sickness and serum-sickness-like reactions
Overview & Definition
Picture a four-year-old who finished a course of cefaclor for an ear infection eight days ago and now returns with a fever, a blotchy moving rash over his trunk and swollen stiff knees. He looks miserable but not toxic, and his mother is frightened. That combination — a delayed triad of rash, fever and arthralgia arriving a week or two after a drug — is the fingerprint of the serum-sickness picture, and recognising its timing is what separates it from the rashes that arrive within hours (immediate allergy) or the fevers that arrive without a rash (infection). [8] [14]
The name "serum sickness" comes from the era when horse serum was used to treat diphtheria: children injected with foreign animal protein developed fever, rash and joint pain about a week later. The mechanism is a Type III immune-complex hypersensitivity — the foreign antigen combines with newly formed antibody, the resulting complexes deposit in blood-vessel walls and joints, complement is activated and consumed, and the inflammatory fallout produces the clinical triad. The classic prospective studies of human serum sickness in patients treated with equine anti-thymocyte globulin defined this mechanism and its immunology, and they remain the reference point for what "true" serum sickness means. [5] [6]
The "serum-sickness-like reaction" is the modern paediatric reality. It produces a clinically identical triad of rash, fever and arthralgia, but the complement level is normal and circulating immune complexes are not found. Cefaclor, a second-generation cephalosporin once widely used in young children, is the paradigmatic cause, and the paediatric literature on cefaclor SSLR is what built our modern understanding of the condition. The distinction matters because it changes the avoidance decision: a true serum-sickness reaction from a monoclonal antibody should not be re-challenged, whereas many children with a cefaclor SSLR can tolerate a different antibiotic and even, in selected cases, a graded re-challenge. [7] [8] [1]
The numbers that frame the problem
References14ShowHide
- [1]Norton AE Serum Sickness-Like Reactions in Children-Is Lifelong Avoidance Indicated? Journal of Allergy and Clinical Immunology: In Practice, 2025.PMID 39978544
- [2]Khalaf R Serum Sickness-Like Reactions Clinical Characteristics and Management: A Systematic Review. Journal of Allergy and Clinical Immunology: In Practice, 2025.PMID 40032232
- [3]Delli Colli L Differentiating Between β-Lactam-Induced Serum Sickness-Like Reactions and Viral Exanthem in Children Using a Graded Oral Challenge. Journal of Allergy and Clinical Immunology: In Practice, 2021.PMID 32898711
- [4]Chatzigrigoriadis S Serum Sickness-Like Reaction: A Narrative Review of Epidemiology, Immunopathogenesis, Diagnostic Challenges, and Therapeutic Approaches. Clinical Practice, 2025.PMID 41148776
- [5]Lawley TJ A prospective clinical and immunologic analysis of patients with serum sickness. New England Journal of Medicine, 1984.PMID 6387492
- [6]Bielory L Human serum sickness: a prospective analysis of 35 patients treated with equine anti-thymocyte globulin for bone marrow failure. Medicine (Baltimore), 1988.PMID 3257288
- [7]Kearns GL Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility. Journal of Pediatrics, 1994.PMID 7965438
- [8]Hebert AA Serum sickness-like reactions from cefaclor in children. Journal of the American Academy of Dermatology, 1991.PMID 1802903
- [9]Kearns GL Serum sickness-like reaction to cefaclor: lack of in vitro cross-reactivity with loracarbef. Clinical Pharmacology and Therapeutics, 1998.PMID 9663184
- [10]Yorulmaz A Demographic and clinical characteristics of patients with serum sickness-like reaction. Clinical Rheumatology, 2018.PMID 28795234
- [11]Bayer G Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study. European Journal of Internal Medicine, 2019.PMID 31279430
- [12]Pichler WJ Immune pathomechanism and classification of drug hypersensitivity. Allergy, 2019.PMID 30843233
- [13]Robson M Updates in Pediatric Drug Allergy. Current Allergy and Asthma Reports, 2026.PMID 41706240
- [14]Friedman N Serum Sickness and Serum Sickness-Like Reactions Presenting to Pediatric Hospital. Clinical Pediatrics, 2025.PMID 39101282